Insulin action in the vasculature: Physiology and pathophysiology

Journal of Vascular Research

Volumn 38, Issue 5, 2001, Pages 415-422

  Mather, Kieren ^a   Anderson, Todd J ^b   Verma, Subodh ^c,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Diabetes; Endothelial function; Endothelin 1; Insulin; Insulin resistance

Indexed keywords

ENDOTHELIN 1; GLUCOSE; INSULIN; METFORMIN; NITRIC OXIDE; ROSIGLITAZONE; TROGLITAZONE;

BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CELL GROWTH; CELL MIGRATION; DISEASE ASSOCIATION; DRUG MECHANISM; ENDOTHELIUM LESION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR DISEASE; VASCULARIZATION; VASODILATATION;

ANIMALS; BLOOD VESSELS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE;

EID: 0035743353     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051074     Document Type: Review

References (86)

1. Insulin and risk of cardiovascular disease - A meta-analysis
2. Hyperinsulinemia, insulin resistance, and hyperglycemia: Contributing factors in the pathogenesis of hypertension and atherosclerosis
3. Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease
4. Insulin as a vascular and sympathoexcitatory hormone: Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity
5. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
6. Epidemiology of insulin resistance and its relation to coronary artery disease
7. Type 2 diabetes care: The role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention
8. Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: Ending the heartache
9. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats
10. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy
11. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus
12. Kinetics of in vivo muscle insulin-mediated glucose uptake in human obesity
13. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM
14. Nitric oxide release accounts for insulin's vascular effects in humans
15. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release
16. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells
17. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells
18. The Akt kinase signals directly to endothelial nitric oxide synthase
19. Insulin induced vasodilation is dependent upon tetrahydrobiopterin synthesis
20. Insulin-induced vasodilatation: Physiology or pharmacology?
21. Insulin-mediated vasodilation: Why one's physiology could be the other's pharmacology
22. Role of blood flow in the regulation of muscle glucose uptake
23. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance
24. Insulin action is associated with endothelial function in hypertension and type 2 diabetes
25. Evidence for physiologic coupling of limb blood flow and insulin mediated glucose metabolism
26. Hemodynamic actions of insulin in rat skeletal muscle: Evidence for capillary recruitment
27. Intact insulin stimulation of skeletal muscle blood flow, its heterogeneity and redistribution, but not of glucose uptake in non-insulin-dependent diabetes mellitus
28. Insulin-mediated changes in microvascular flow distribution assessed by contrast ultrasound
29. Nitric oxide synthase: Role in the genesis of vascular disease
30. The endothelium and control of blood vessel function in health and disease
31. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus
32. Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity
33. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance
34. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension
35. Reduced capacity and affinity of skeletal muscle for insulin-mediated glucose uptake in noninsulin-dependent diabetic subjects. Effects of insulin therapy
36. Insulin-mediated vasodilation and glucose uptake are functionally linked in humans
37. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation
38. Induction of insulin resistance by glucosamine reduces blood flow but not interstitial levels of either glucose or insulin
39. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1
40. Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome
41. Metformin
42. Metformin treatment corrects vascular insulin resistance in hypertension
43. Effect of modulating insulin resistance on endothelial function in type 2 diabetes mellitus
44. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus
45. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone
46. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro
47. Prevalence of insulin resistance in metabolic disorders: The Bruneck study
48. Decreased blood flow but unaltered insulin sensitivity of glucose uptake in skeletal muscle of chronic smokers
49. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus
50. 2-imbalance in aortas of insulin-resistant rats
51. Endothelin antagonism uncovers insulin-mediated vasorelaxation in-vitro and in-vivo
52. The L-arginine-nitric oxide pathway
53. Insulin stimulates production and secretion of endothelin from bovine endothelial cells
54. Insulin influences immunoreactive endothelin release by human vascular smooth muscle cells
55. Exogenous hyperinsulinemia causes insulin resistance, hyperendothelinemia, and subsequent hypertension in rats
56. Insulin stimulates both endothelin and nitric oxide activity in the human forearm
57. Plasma endothelin levels in NIDDM patients with macroangiopathy
58. Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease
59. Circulating endothelin-1 levels in lean non-insulin-dependent diabetic patients. Influence of ACE inhibition
60. Circulating endothelin-1 levels in obese patients with the metabolic syndrome
61. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes
62. Plasma endothelin-1 levels in patients with diabetes mellitus with or without vascular complication
63. Plasma endothelin in NIDDM patients with and without complications
64. Plasma endothelin-1 levels in obese hypertensive and normotensive men
65. Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs
66. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome
67. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo
68. Endogenous insulin modulates circulating endothelin-1 concentrations in humans
69. Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men
70. Lack of acute insulin effect on plasma endothelin-1 levels in humans
71. Increasing neopterin and decreasing endothelin-1 in plasma during insulin infusion in women
72. Effects of acute euglycemic hyperinsulinemia on urinary nitrite/nitrate excretion and plasma endothelin-1 levels in men with essential hypertension and normotensive controls
73. Enhanced endothelin-1 response and receptor expression in small mesenteric arteries of insulin-resistant rats
74. Endothelin-induced venoconstriction is unaffected by type 2-diabetes: In vivo effect of histamine on the endothelin action on veins
75. Vasoconstriction to endothelin-1 is blunted in non-insulin-dependent diabetes: A dose-response study
76. Vasoconstriction to endogenous endothelin-1 is impaired in patients with type II diabetes mellitus
77. ET-1A receptor blockade improves endothelium-dependent vasodilation in insulin resistant obese and type 2 diabetic patients
78. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells
79. Vasoactive hormones induce nitric oxide synthase mRNA expression and nitric oxide production in human endothelial cells and monocytes
80. Tyrosine-kinase-dependent regulation of the nitric oxide synthase gene by endothelin-1 in human endothelial cells
81. Insulin increases endothelin-1-evoked intracellular free calcium responses by increased ET(A) receptor expression in rat aortic smooth muscle cells
82. Termination of endothelin signaling: Role of nitric oxide
83. Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells
84. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
85. Insulin resistance and hypertension: Pharmacological and mechanistic studies
86. Effects of chronic endothelin blockade in hyperinsulinemic, hypertensive rats